CCR7/CCL21 Migration on Fibronectin is Mediated by Phospholipase Cgamma1 and ERK1/2 in Primary T Lymphocytes
Overview
Affiliations
CCR7 binds to its cognate ligand, CCL21, to mediate the migration of circulating naive T lymphocytes to the lymph nodes. T lymphocytes can bind to fibronectin, a constituent of lymph nodes, via their β1 integrins, which is a primary mechanism of T lymphocyte migration; however, the signaling pathways involved are unclear. We report that rapid (within 2 min) and transient phosphorylation of ERK1/2 is required for T cell migration on fibronectin in response to CCL21. Conversely, prevention of ERK1/2 phosphorylation by inhibition of its kinase, MAPK/MEK, prevented T lymphocyte migration. Previous studies have suggested that phospholipase Cγ1 (PLCγ1) can mediate phosphorylation of ERK1/2, which is required for β1 integrin activation. Paradoxically, we found that inhibition of PLCγ1 phosphorylation by the general PLC inhibitor U73122 was associated with a delayed and reduced phosphorylation of ERK1/2 and reduced migration of T lymphocytes on fibronectin. To further characterize the relationship between ERK1/2 and PLCγ1, we reduced PLCγ1 levels by 85% using shRNA and observed a reduced phosphorylation of ERK1/2 and a significant loss of CCR7-mediated migration of T lymphocytes on fibronectin. In addition, we found that inhibition of ERK1/2 phosphorylation by U0126 resulted in a decreased phosphorylation of PLCγ1, suggesting a feedback loop between ERK1/2 and PLCγ1. Overall, these results suggest that the CCR7 signaling pathway leading to T lymphocyte migration on fibronectin is a β1 integrin-dependent pathway involving transient ERK1/2 phosphorylation, which is modulated by PLCγ1.
Cardona C, Rodriguez A, Torres V, Sanchez A, Torres A, Vazquez A Int J Mol Sci. 2024; 25(17).
PMID: 39273598 PMC: 11395280. DOI: 10.3390/ijms25179649.
Chung Y, Zhao Z, Jung E, Omole A, Wang H, Sutorus L Adv Sci (Weinh). 2024; 11(18):e2308237.
PMID: 38430536 PMC: 11095214. DOI: 10.1002/advs.202308237.
Zhao H, Sun M, Zhang Y, Kong W, Fan L, Wang K Aging Dis. 2023; 15(1):115-152.
PMID: 37307828 PMC: 10796102. DOI: 10.14336/AD.2023.0516.
Rodriguez-Fernandez J, Criado-Garcia O Front Immunol. 2022; 13:1001086.
PMID: 36341452 PMC: 9630654. DOI: 10.3389/fimmu.2022.1001086.
Development of a human antibody that exhibits antagonistic activity toward CC chemokine receptor 7.
Jang M, Ismail N, Yu Y Antib Ther. 2022; 5(3):192-201.
PMID: 35967907 PMC: 9372883. DOI: 10.1093/abt/tbac016.